Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Lipotoxic lethal and sublethal stress signaling in hepatocytes: relevance to NASH pathogenesis
Petra Hirsova, Samar H. Ibrabim, Gregory J. Gores, et al.
Journal of Lipid Research (2016) Vol. 57, Iss. 10, pp. 1758-1770
Open Access | Times Cited: 228

Showing 1-25 of 228 citing articles:

Mechanisms of NAFLD development and therapeutic strategies
Scott L. Friedman, Brent A. Neuschwander‐Tetri, Mary E. Rinella, et al.
Nature Medicine (2018) Vol. 24, Iss. 7, pp. 908-922
Open Access | Times Cited: 3289
Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease
Cynthia Lebeaupin, Déborah Vallée, Younis Hazari, et al.
Journal of Hepatology (2018) Vol. 69, Iss. 4, pp. 927-947
Open Access | Times Cited: 753
Triggering and resolution of inflammation in NASH
Susanne Schuster, Daniel Cabrera, Marco Arrese, et al.
Nature Reviews Gastroenterology & Hepatology (2018) Vol. 15, Iss. 6, pp. 349-364
Closed Access | Times Cited: 737
Lipotoxicity and the gut-liver axis in NASH pathogenesis
Fabio Marra, Gianluca Svegliati‐Baroni
Journal of Hepatology (2017) Vol. 68, Iss. 2, pp. 280-295
Closed Access | Times Cited: 689
Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease
Juan Pablo Arab, Marco Arrese, Michael Trauner
Annual Review of Pathology Mechanisms of Disease (2018) Vol. 13, Iss. 1, pp. 321-350
Open Access | Times Cited: 479
Molecular pathways of nonalcoholic fatty liver disease development and progression
Fernando Bessone, María Valeria Razori, Marcelo G. Roma
Cellular and Molecular Life Sciences (2018) Vol. 76, Iss. 1, pp. 99-128
Closed Access | Times Cited: 468
Past, present and future perspectives in nonalcoholic fatty liver disease
Arun J. Sanyal
Nature Reviews Gastroenterology & Hepatology (2019) Vol. 16, Iss. 6, pp. 377-386
Closed Access | Times Cited: 463
Determinants of fibrosis progression and regression in NASH
Detlef Schuppan, Rambabu Surabattula, Xiaoyu Wang
Journal of Hepatology (2017) Vol. 68, Iss. 2, pp. 238-250
Closed Access | Times Cited: 419
Non-alcoholic fatty liver disease
Brent A. Neuschwander‐Tetri
BMC Medicine (2017) Vol. 15, Iss. 1
Open Access | Times Cited: 408
Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH
I. Pierantonelli, Gianluca Svegliati‐Baroni
Transplantation (2018) Vol. 103, Iss. 1, pp. e1-e13
Open Access | Times Cited: 371
How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease?
Yana Geng, Klaas Nico Faber, Vincent E. de Meijer, et al.
Hepatology International (2021) Vol. 15, Iss. 1, pp. 21-35
Open Access | Times Cited: 253
Ferroptosis Affects the Progression of Nonalcoholic Steatohepatitis via the Modulation of Lipid Peroxidation–Mediated Cell Death in Mice
Jing Qi, Jong-Won Kim, Zixiong Zhou, et al.
American Journal Of Pathology (2019) Vol. 190, Iss. 1, pp. 68-81
Open Access | Times Cited: 252
Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation
Samar H. Ibrahim, Petra Hirsova, Gregory J. Gores
Gut (2018) Vol. 67, Iss. 5, pp. 963-972
Open Access | Times Cited: 232
Apoptosis and non-alcoholic fatty liver diseases
Tatsuo Kanda, Shunichi Matsuoka, Motomi Yamazaki, et al.
World Journal of Gastroenterology (2018) Vol. 24, Iss. 25, pp. 2661-2672
Open Access | Times Cited: 228
High fat diet-triggered non-alcoholic fatty liver disease: A review of proposed mechanisms
Cai-Yu Lian, Zhenzhen Zhai, Zifa Li, et al.
Chemico-Biological Interactions (2020) Vol. 330, pp. 109199-109199
Closed Access | Times Cited: 216
A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis
Stephen A. Harrison, Zachary Goodman, Abdul Jabbar, et al.
Journal of Hepatology (2019) Vol. 72, Iss. 5, pp. 816-827
Closed Access | Times Cited: 205
Challenges and opportunities in NASH drug development
Stephen A. Harrison, Alina M. Allen, Julie Dubourg, et al.
Nature Medicine (2023) Vol. 29, Iss. 3, pp. 562-573
Closed Access | Times Cited: 198
Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)
Xiaohan Xu, Kyle L. Poulsen, Lijuan Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 195
Lipidomic biomarkers and mechanisms of lipotoxicity in non-alcoholic fatty liver disease
Gianluca Svegliati‐Baroni, I. Pierantonelli, Pierangelo Torquato, et al.
Free Radical Biology and Medicine (2019) Vol. 144, pp. 293-309
Closed Access | Times Cited: 194
The circadian clock and liver function in health and disease
Atish Mukherji, Shannon M. Bailey, Bart Staels, et al.
Journal of Hepatology (2019) Vol. 71, Iss. 1, pp. 200-211
Open Access | Times Cited: 178
Pathophysiology of obesity and its associated diseases
Xin Jin, Tingting Qiu, Li Li, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 13, Iss. 6, pp. 2403-2424
Open Access | Times Cited: 170
Therapeutic Landscape for NAFLD in 2020
Brent A. Neuschwander‐Tetri
Gastroenterology (2020) Vol. 158, Iss. 7, pp. 1984-1998.e3
Closed Access | Times Cited: 168
Macrophage functional diversity in NAFLD — more than inflammation
Emelie Barreby, Ping Chen, Myriam Aouadi
Nature Reviews Endocrinology (2022) Vol. 18, Iss. 8, pp. 461-472
Closed Access | Times Cited: 153
IRE1A Stimulates Hepatocyte-Derived Extracellular Vesicles That Promote Inflammation in Mice With Steatohepatitis
Debanjali Dasgupta, Yasuhiko Nakao, Amy S. Mauer, et al.
Gastroenterology (2020) Vol. 159, Iss. 4, pp. 1487-1503.e17
Open Access | Times Cited: 144
Novel therapeutic targets for cholestatic and fatty liver disease
Michael Trauner, Claudia Fuchs
Gut (2021) Vol. 71, Iss. 1, pp. 194-209
Open Access | Times Cited: 133
Page 1 - Next Page

Scroll to top